Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314939 | 1.00 | KDR (0.40) | KDREPHB4FGFR1MAPK14ACP1 | |
| SCHEMBL5266372 | 0.86 | EPHB4 (0.44) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5312681 | 0.81 | EPHB4 (0.37) | KDREPHB4FGFR1MAPK14ACP1 | |
| SCHEMBL5914429 | 0.80 | EPHB4 (0.42) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5310133 | 0.80 | EPHB4 (0.38) | KDREPHB4FGFR1MAPK14ACP1 | |
| SCHEMBL5315338 | 0.80 | EPHB4 (0.38) | KDREPHB4FGFR1MAPK14ACP1 | |
| SCHEMBL14396485 | 0.80 | EPHB4 (0.40) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL3922932 | 0.79 | KDR (0.39) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5265551 | 0.79 | EPHB4 (0.42) | KDREPHB4FGFR1MAPK14 | |
| SCHEMBL5266761 | 0.78 | EPHB4 (0.39) | KDREPHB4FGFR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | KDR 210/4885EPHB4 1411/4885FGFR1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.